复星医药
(600196)
| 流通市值：503.78亿 | | | 总市值：635.03亿 |
| 流通股本：21.18亿 | | | 总股本：26.70亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 20,441,970,386 | 10,073,223,477.03 | 41,661,612,748.15 | 29,393,385,360.91 |
| 营业收入 | 20,441,970,386 | 10,073,223,477.03 | 41,661,612,748.15 | 29,393,385,360.91 |
| 二、营业总成本 | 19,682,627,988.3 | 9,532,295,160.5 | 40,087,325,053.49 | 28,415,595,587.6 |
| 营业成本 | 10,288,188,559.9 | 5,066,739,286.46 | 20,800,103,192.22 | 15,225,462,362.51 |
| 税金及附加 | 158,507,405.06 | 74,610,767.33 | 344,617,180.44 | 240,949,647.3 |
| 销售费用 | 4,418,124,669.63 | 2,254,592,699.25 | 9,193,022,306.29 | 6,269,283,998.05 |
| 管理费用 | 2,199,818,899.79 | 1,017,224,018.98 | 4,583,601,754.23 | 3,067,356,397.76 |
| 研发费用 | 2,086,925,316.22 | 896,787,372.5 | 4,012,555,580.82 | 2,729,517,164.8 |
| 财务费用 | 531,063,137.7 | 222,341,015.98 | 1,153,425,039.49 | 883,026,017.18 |
| 其中:利息费用 | 607,386,380.77 | 296,510,967.36 | 1,265,350,720.93 | 974,025,974.09 |
| 其中:利息收入 | 135,223,968.44 | 72,141,643.38 | 300,503,664.21 | 236,793,412.05 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 273,651,844.51 | 160,915,938.1 | -322,268,457.29 | -375,106,548.93 |
| 加:投资收益 | 1,493,305,373.4 | 617,532,169.82 | 3,763,778,024.02 | 3,095,360,303.24 |
| 资产处置收益 | 195,231.96 | 1,371,616.94 | 69,350,406.88 | 62,764,603.19 |
| 资产减值损失(新) | -14,942,862.94 | 4,113,842.22 | -150,063,042.97 | -84,326,905.63 |
| 信用减值损失(新) | -28,123,472.13 | -5,056,060.11 | -125,174,547.55 | -47,122,378.6 |
| 其他收益 | 132,512,562.88 | 55,570,376.53 | 418,441,261.84 | 277,406,532.99 |
| 四、营业利润 | 2,615,941,075.38 | 1,375,376,200.03 | 5,228,351,339.59 | 3,906,765,379.57 |
| 加:营业外收入 | 23,951,987.93 | 7,059,726.87 | 46,772,747.6 | 17,991,026.97 |
| 减:营业外支出 | 53,321,156.38 | 24,891,490.73 | 163,140,823.32 | 87,412,924.75 |
| 五、利润总额 | 2,586,571,906.93 | 1,357,544,436.17 | 5,111,983,263.87 | 3,837,343,481.79 |
| 减:所得税费用 | 437,643,476.61 | 277,916,582.03 | 864,053,635.49 | 781,251,530.11 |
| 六、净利润 | 2,148,928,430.32 | 1,079,627,854.14 | 4,247,929,628.38 | 3,056,091,951.68 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 2,148,928,430.32 | 1,079,627,854.14 | 4,247,929,628.38 | 3,056,091,951.68 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 1,721,467,719.58 | 870,825,581.84 | 3,370,561,562.61 | 2,523,293,508.22 |
| 少数股东损益 | 427,460,710.74 | 208,802,272.3 | 877,368,065.77 | 532,798,443.46 |
| 扣除非经常损益后的净利润 | 1,144,165,735.05 | 500,532,364.71 | 2,340,160,476.91 | 1,573,243,380.88 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.65 | 0.33 | 1.27 | 0.95 |
| (二)稀释每股收益 | 0.65 | 0.33 | 1.27 | 0.95 |
| 八、其他综合收益 | -913,684,904.03 | -616,755,016.63 | -675,759,872.93 | -385,229,723.22 |
| 归属于母公司股东的其他综合收益 | -627,965,238.86 | -392,162,147.5 | -456,410,888.81 | -280,830,700.9 |
| 九、综合收益总额 | 1,235,243,526.29 | 462,872,837.51 | 3,572,169,755.45 | 2,670,862,228.46 |
| 归属于母公司股东的综合收益总额 | 1,093,502,480.72 | 478,663,434.34 | 2,914,150,673.8 | 2,242,462,807.32 |
| 归属于少数股东的综合收益总额 | 141,741,045.57 | -15,790,596.83 | 658,019,081.65 | 428,399,421.14 |
| 公告日期 | 2026-08-26 | 2026-04-29 | 2026-03-25 | 2025-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |